The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Research Report 2025
Synopsis
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age.
The global Polycystic Ovarian Syndrome (PCOS) Therapeutics market was valued at US$ 3740.4 million in 2023 and is anticipated to reach US$ 4636.6 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Polycystic Ovarian Syndrome (PCOS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polycystic Ovarian Syndrome (PCOS) Therapeutics.
Report Scope
The Polycystic Ovarian Syndrome (PCOS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Polycystic Ovarian Syndrome (PCOS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited
Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Polycystic Ovarian Syndrome (PCOS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age.
The global Polycystic Ovarian Syndrome (PCOS) Therapeutics market was valued at US$ 3740.4 million in 2023 and is anticipated to reach US$ 4636.6 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Polycystic Ovarian Syndrome (PCOS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polycystic Ovarian Syndrome (PCOS) Therapeutics.
Report Scope
The Polycystic Ovarian Syndrome (PCOS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Polycystic Ovarian Syndrome (PCOS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited
Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Polycystic Ovarian Syndrome (PCOS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Contraceptive
1.2.3 Ovulation Inducing Agents
1.2.4 Facial Hair Growth Inhibitor
1.2.5 Insulin Sensitizing Agent
1.3 Market by Application
1.3.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Perspective (2019-2030)
2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Growth Trends by Region
2.2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Dynamics
2.3.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Industry Trends
2.3.2 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Drivers
2.3.3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Challenges
2.3.4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue
3.1.1 Global Top Polycystic Ovarian Syndrome (PCOS) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue
3.4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio
3.4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Polycystic Ovarian Syndrome (PCOS) Therapeutics Revenue in 2023
3.5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Polycystic Ovarian Syndrome (PCOS) Therapeutics Product Solution and Service
3.7 Date of Enter into Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Type
4.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Polycystic Ovarian Syndrome (PCOS) Therapeutics Breakdown Data by Application
5.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2019-2030)
6.2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2019-2024)
6.4 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2019-2030)
7.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2019-2030)
9.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.1.4 Bristol Myers Squibb Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Crinetics Pharmaceuticals, Inc.
11.2.1 Crinetics Pharmaceuticals, Inc. Company Detail
11.2.2 Crinetics Pharmaceuticals, Inc. Business Overview
11.2.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.2.4 Crinetics Pharmaceuticals, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.2.5 Crinetics Pharmaceuticals, Inc. Recent Development
11.3 EffRx, Inc.
11.3.1 EffRx, Inc. Company Detail
11.3.2 EffRx, Inc. Business Overview
11.3.3 EffRx, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.3.4 EffRx, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.3.5 EffRx, Inc. Recent Development
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals Company Detail
11.4.2 Ferring Pharmaceuticals Business Overview
11.4.3 Ferring Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.4.4 Ferring Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.4.5 Ferring Pharmaceuticals Recent Development
11.5 Merck KGaA
11.5.1 Merck KGaA Company Detail
11.5.2 Merck KGaA Business Overview
11.5.3 Merck KGaA Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.5.4 Merck KGaA Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.5.5 Merck KGaA Recent Development
11.6 Neurocrine Biosciences, Inc.
11.6.1 Neurocrine Biosciences, Inc. Company Detail
11.6.2 Neurocrine Biosciences, Inc. Business Overview
11.6.3 Neurocrine Biosciences, Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.6.4 Neurocrine Biosciences, Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.6.5 Neurocrine Biosciences, Inc. Recent Development
11.7 Novartis Pharmaceuticals
11.7.1 Novartis Pharmaceuticals Company Detail
11.7.2 Novartis Pharmaceuticals Business Overview
11.7.3 Novartis Pharmaceuticals Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.7.4 Novartis Pharmaceuticals Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.7.5 Novartis Pharmaceuticals Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.8.4 Pfizer Inc. Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.8.5 Pfizer Inc. Recent Development
11.9 Sanofi Aventis
11.9.1 Sanofi Aventis Company Detail
11.9.2 Sanofi Aventis Business Overview
11.9.3 Sanofi Aventis Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.9.4 Sanofi Aventis Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.9.5 Sanofi Aventis Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Detail
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Polycystic Ovarian Syndrome (PCOS) Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Polycystic Ovarian Syndrome (PCOS) Therapeutics Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
